amikacin
therapy
exacerbation
pseudomonas
aeruginosa
infection
patient
cystic
fibrosis
amikacin
new
semisynthetic
aminoglycoside
antibiotic
activity
pseudomonas
aeruginosa
used
treat
acute
exacerbation
chronic
pulmonary
infection
patient
cystic
fibrosis
patient
ranged
year
age
mucoid
p
aeruginosa
isolated
sputum
amikacin
dose
usually
mg
kg
every
eight
hour
increased
mg
kg
carbenicillin
added
selected
case
depending
clinical
course
although
p
aeruginosa
eliminated
patient
sputum
except
two
case
good
clinical
response
course
significant
improvement
chest
x
ray
film
spirometry
arterial
oxygen
tension
documented
course
one
instance
serum
creatinine
level
elevation
could
attributed
antibiotic
two
patient
showed
minimal
db
unilateral
high
frequency
hearing
loss
serial
audiogram
activity
many
gentamicin
resistant
strain
high
blood
level
among
attractive
property
amikacin
amikacin
clinically
effective
treating
pseudomonas
associated
pulmonary
infection
complicating
cystic
fibrosis
